

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address; COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/682,921	09/682,921 11/01/2001		Adeyinka Adedeji	08CN06024-2 3493			
23413	7590	01/13/2003					
CANTOR		•	EXAMINER				
55 GRIFFIN BLOOMFIE			MULLIS, JEFFREY C				
				ART UNIT	PAPER NUMBER		
				1711			
				DATE MAILED: 01/13/2003			

2

Please find below and/or attached an Office communication concerning this application or proceeding.

ł			Application	n No.	Applicant(s)	
		•	09/682,92	1	ADEDEJI ET AL.	•
	, Offic	Action Summary	Examiner		Art Unit	
•			Jeffrey C.		1711	
eriod fo		LING DATE of this communication app	ears on the	cover sheet with the c	orresp ndence ad	dress
THE N - Exten after S - If the - If NO - Failur - Any re	MAILING Dates in the result of the result of the reply period for reply period for reply to the reply received by received by received by the received by the received by rece	O STATUTORY PERIOD FOR REPLY DATE OF THIS COMMUNICATION. may be available under the provisions of 37 CFR 1.13. HS from the mailing date of this communication. y specified above is less than thirty (30) days, a reply by is specified above, the maximum statutory period vin the set or extended period for reply will, by statute by the Office later than three months after the mailing adjustment. See 37 CFR 1.704(b).	36(a). In no eve y within the statu will apply and wil s, cause the appli	nt, however, may a reply be tim tory minimum of thirty (30) day: expire SIX (6) MONTHS from cation to become ABANDONE	nely filed s will be considered timel the mailing date of this co D (35 U.S.C. § 133).	
1)⊠	Respons	ive to communication(s) filed on 29 A	August 2002	2.		
2a) <u></u> □	This action	on is FINAL . 2b)⊠ Th	is action is	non-final.		
3)□ Dispositio	closed in	s application is in condition for allowa accordance with the practice under a ims				e merits is
4)🛛	Claim(s)	<u>1-46</u> is/are pending in the application	١.			
4	4a) Of the	above claim(s) is/are withdraw	wn from cor	sideration.		
5)[]	Claim(s) _	is/are allowed.				
6)⊠	Claim(s) 1	<u>1-46</u> is/are rejected.				
7) 🗌	Claim(s) _	is/are objected to.				
8)[Claim(s) _	are subject to restriction and/o	r election re	quirement.		
Application	on Papers	S				
9)[] 7	The specifi	ication is objected to by the Examine	r.			
10)[] 7	The drawin	ng(s) filed on is/are: a)□ accep	oted or b)□	objected to by the Exa	miner.	
	• •	may not request that any objection to the		•	, ,	
11) 🗌 T	The propos	sed drawing correction filed on	_ is: a)☐ ap	proved b)⊡ disappro	ved by the Examin	er.
	If approve	ed, corrected drawings are required in rep	ply to this Of	ice action.		
12)∐ T	The oath o	r declaration is objected to by the Ex	aminer.			
Priority u	ınder 35 U	J.S.C. §§ 119 and 120				
13)	Acknowle	dgment is made of a claim for foreign	n priority un	der 35 U.S.C. § 119(a)-(d) or (f).	
a)[All b)] Some * c) ☐ None of:				
	1. Cer	tified copies of the priority documents	s have beei	received.		
	2. Cer	tified copies of the priority documents	s have beer	received in Applicati	on No	
		oies of the certified copies of the prior application from the International Bur ached detailed Office action for a list	reau (PCT i	Rule 17.2(a)).		Stage
14)∐ A	cknowledg	gment is made of a claim for domesti	c priority un	der 35 U.S.C. § 119(e	e) (to a provisional	application).
		ranslation of the foreign language pro gment is made of a claim for domesti				·
Attachment		-				
1) Notice 2) Notice 3) Inform	e of Reference of Draftsper nation Disclos	ces Cited (PTO-892) rson's Patent Drawing Review (PTO-948) sure Statement(s) (PTO-1449) Paper No(s)	<u>26</u> .		(PTO-413) Paper No Patent Application (PT	
J.S. Patent and Tra PTO-326 (Rev		Office Ac	tion Summar	y	Part o	f Paper No. 7

Serial No. 09/682,921
Art Unit 1711

Applicants are requested to change the docket number in paragraph 76 to an application number if possible.

Claims 42-46 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification as filed does not disclose a "reaction product" of the various materials recited in claims 42-46 and does not disclose how to make such a reaction product.

Claims 14, 26-29 and 31 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regard as the invention.

The term "naphthyl group including" renders at least claim
14 unclear in that it is not recited what the term "including"
refers to.

Claims 26-29 are unclear since the ethylene/alphaolefin copolymer is embraced by the polyolefin of the independent claims and it is therefore unclear if the ethylene/alphaolefin copolymer is meant to be a material in addition to the polyolefin of the independent claim.

Serial No. 09/682,921
Art Unit 1711

The term "substantially free" as recited in at least claim 31 renders at least claim 31 unclear since it is subjective as to how much substantially would embrace.

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-46 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Maruyama et al. (USP 5,081,187).

Patentees broadly disclose applicants' components in applicants' amounts at column 8 lines 16-55 and at column 4 lines 60-64 discloses that part of the polyphenylene ether may be replaced with polyarylene ether. The amount of aromatic block recited by the instant claims is disclosed at column 5 lines 52-57. Note Example 1 which is identical to that of applicants' claims and contains a hydrogenated and non-hydrogenated block copolymer but does not disclose how much vinyl block is present in the block copolymers and does not disclose the presence of polyvinyl aromatic compound, although as set out above, these features are disclosed by patentees' specification.

Art Unit 1711

Patentees do not disclose any specific examples containing applicants' materials in combination in applicants' amounts. However it would have been obvious to a practitioner having ordinary skill in the art at the time of the invention to use applicants' amounts of materials based on the disclosure of Maruyama et al. since Maruyama et al. discloses that such materials in applicants' amounts may be used and in the expectation of adequate results absent any showing of surprising or unexpected results.

The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and In re Goodman, 29 USPQ 2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-46 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-43 of copending application Serial No. 09/682,926. Although the conflicting claims are not identical, they are not patentably distinct from each other because choice

Art Unit 1711

of percentages of the instant application from those of the copending application would have been obvious to a practitioner
having ordinary skill in the art at the time of the invention in
that the percentages overlap and furthermore in that it requires
only routine experimentation to find the optimum or workable
range of a result effective variable absent any showing of
surprising or unexpected results.

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1-46 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-36 of copending application Serial No. 09/682,923. Although the conflicting claims are not identical, they are not patentably distinct from each other because choice of percentages of the instant application from those of the copending application would have been obvious to a practitioner having ordinary skill in the art at the time of the invention in that the percentages overlap and furthermore in that it requires only routine experimentation to find the optimum or workable range of a result effective variable absent any showing of surprising or unexpected results.

Serial No. 09/682,921

Art Unit 1711

This is a *provisional* obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Any inquiry concerning this communication should be directed to Jeffrey Mullis at telephone number (703) 308-2820.

J. Mullis:cdc

January 12, 2003

